Pharmaceuticals

Retinal Disorder Treatment Market 2025–2029: Tracking 7.2% CAGR Toward $1.71 Billion in Revenue

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the retinal disorder treatment market from 2025–2034 with trusted insights from The Business Research Company

How Will The Retinal Disorder Treatment Market Size Evolve Between Now And 2029?

The histone deacetylase inhibitors market has demonstrated robust expansion in recent years. It is anticipated to grow from $1.2 billion in 2024 to $1.29 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.2%. The growth observed in previous periods stems from elements such as regulatory backing and expedited approvals, the increasing occurrence of cancer, greater financial contributions to cancer research, an broadening of therapeutic uses, and higher spending on healthcare infrastructure.

The histone deacetylase inhibitors market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $1.71 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.2%. Several factors are expected to drive this growth during the forecast period, including increased investment in biotechnology, the expanding aging population, supportive regulatory approvals, expedited drug approval procedures, advancements in drug delivery systems, and the broadening of therapeutic applications. Key trends anticipated within the forecast period encompass the incorporation of wearable technologies for patient health monitoring, breakthroughs in nanotechnology and drug delivery approaches, progress in biomarker identification and validation, the application of artificial intelligence (AI) and machine learning, and next-generation sequencing.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp

Which Key Drivers Are Powering Growth In The Retinal Disorder Treatment Market?

The histone deacetylase inhibitors market is anticipated to expand due to the growing occurrence of cancer. This increasing incidence of cancer is largely attributed to aging populations, greater exposure to risk factors such as tobacco, diet, and environmental pollutants, and enhanced diagnostic methods that lead to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by modifying chromatin structure, which activates tumor suppressor genes and suppresses oncogenes, thereby inducing cell cycle arrest and apoptosis in cancer cells. For instance, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases were predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising incidence of cancer is propelling the growth of the histone deacetylase inhibitors market.

How Is The Global Retinal Disorder Treatment Market Structured By Key Segments?

The histone deacetylase inhibitors market covered in this report is segmented –

1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Oncology, Neurology, Other Applications

5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors

2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors

3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors

4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)

What Future-Focused Trends Are Anticipated In The Retinal Disorder Treatment Market?

Major companies operating within the histone deacetylase inhibitors market are concentrating on the development of innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to broaden treatment options and enhance patient convenience and compliance. An oral histone deacetylase (HDAC) inhibitor is a drug administered by mouth that targets HDAC enzymes involved in gene regulation and holds potential for treating various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, obtained Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat functions as a histone deacetylase (HDAC) inhibitor that mitigates the series of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD. By inhibiting HDAC overactivity, it reduces inflammation and fibrosis while promoting muscle fiber regeneration. The approval is based on the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients on Duvyzat showed a statistically significant decrease in the time required to complete the four-stair climb assessment compared to placebo.

Which Companies Hold A Competitive Edge In The Retinal Disorder Treatment Market?

Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report

Which Region Is Expected To Lead The Retinal Disorder Treatment Market In The Next Few Years?

North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=17170&type=smp

Browse Through More Reports Similar to the Global Retinal Disorder Treatment Market 2025, By The Business Research Company

Her2 Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795